sameAs
Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study.Late-onset hypogonadism.The DIAMOND system in the treatment of type 2 diabetes mellitus in an obese patient.Phenotype and metabolic disorders in polycystic ovary syndrome.Guidelines for menopausal hormone therapy: Recommendations of the Polish Menopause and Andropause Society - state of knowledge as of December 2013.Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-month phase of Lanro-Study.Primary aldosteronism - recent progress and current concepts.Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports.Prevalence of primary hyperparathyroidism among patients with low bone mass.Polish Society of Endocrinology Position statement on endocrine disrupting chemicals (EDCs).Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgery.Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Retroperitoneal hemorrhage from adrenocortical carcinoma as a poor prognostic factor.Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).[Fever as the first symptom of prostatic cancer]The effect of oral ethanol ingestion on the diurnal neurotensin secretion in man.Pituitary apoplexy: endocrine, surgical and oncological emergency. Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas.The incidence of hypogonadotropic hypogonadism in type 2 diabetic men in Polish population[Thyroidectomy as the last chance treatment for life threatening thyrotoxicosis. Case report].Clinical applications of radioimmunoassay of the alpha-subunit of glycoprotein hormones.ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome.The role of combined low-dose dexamethasone suppression test and desmopressin stimulation test in the diagnosis of persistent Cushing's disease. Case report.An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome due to coexistent obesity.Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease.Occult ectopic adrenocorticotropic hormone syndrome.[Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms?[Phenotype of patients with gynecomastia].The effect of blood collection procedure on plasma renin activity (PRA) and concentrations of direct renin (DRC) and aldosterone.Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly.Ghrelin - growth hormone releasing and orexigenic hormone in men declines with age, insulin and with decrease in testosterone concentration.[The relationship between androgens concentrations (testosterone and dehydroepiandrosterone sulfate) and metabolic syndrome in non-obese elderly men].[Gynecomastia--pathogenesis, diagnosis and treatment].[Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].[Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly].In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.
P50
Q30941581-96C343F1-94C9-42DD-96A7-A41A4A52196FQ33903549-17930617-DE92-4817-975D-70329F4BEE06Q34791871-D4960AA9-C2E8-481D-B953-E5F6634214A7Q35825445-76199BED-B8AA-472F-BC5D-0F15F00FE257Q35903489-7064E44B-95FD-4F60-B950-36136D78A0C7Q37601860-8D60DC3B-78A8-4F70-82CE-C5D311009A89Q38134054-E27F965E-410F-46BA-9AD0-6F18871CDE3EQ38178906-1578ECB9-14F5-42DF-BBA9-0122D0063503Q38245853-5F175875-9D18-4D42-8086-16A80CA4FA4BQ38454338-BF0B7336-125F-4B28-9A7A-FE2991717035Q38542005-D192EBB1-BE55-4B76-A1AA-AFFF839B6396Q38702919-8F4EF9BC-8E8E-4C3C-BD21-174F1B08245DQ38765743-537FE76C-6854-4387-9365-3DF2C6E7769BQ38765746-2F6AFC54-12F7-4F2C-8C09-0DE438D209AAQ39526039-4D2645DA-B8B6-49F7-A597-68626977DAE5Q40186992-4C5842CB-46DC-4AD4-A3DD-228BCBFD8D81Q40820489-67DB0AFD-3137-415D-9CA7-9E2D6620981CQ41088908-D313B7AF-00C4-47C1-A9EB-CAE84F8FAC77Q42068007-FAAD9F22-2B27-4E4F-A491-0002FF959FD1Q42114446-3958BA31-A200-48D5-82FF-38C45AF5721DQ42167234-3A2EA2BF-A500-4E4A-96CB-51B1B32BBEB1Q42450082-6EBA56B0-E3C0-4DFF-B610-C2041A73FEF3Q42488639-410592CF-35C3-4249-AFD8-059DA3564D14Q42985939-1867241D-35C1-4E0C-8878-5A4B5FEC968CQ43554290-588D9503-38DA-4056-8749-66BEC0E6C546Q43572004-4764E786-5365-4EFD-A5E5-16C95D6E1233Q43685207-ABC4171C-4C12-4986-B031-1C551CC39AA5Q43814914-51A417FF-0E38-4252-AA80-A49602BC0740Q43852939-5C06E647-F59F-4308-A3A5-33E821DD7AA4Q44627360-97F197BB-CC2E-4E8A-A8BA-067314FD1591Q46118634-C921DA12-86F0-4964-9C71-C445ED00562EQ46605686-C0E90FC7-6A56-4A59-AD82-E9F41DB32D52Q46690815-469431FE-624A-497C-B8E7-A9DCF82B06F9Q46746670-01C9E05C-5487-446A-BD3D-E3B9F810C535Q46746695-61068DEA-D641-4831-91A0-25AF45CD05B5Q46801317-8C09C2E2-0816-4931-9FED-E1D4E3E2BADBQ46848619-A80D5776-DBB7-41AA-B3DA-17E29B10C8B1Q46866631-31FE52ED-B043-4260-955C-AF66A8FFC571Q46866639-B57AEEFE-9DAD-4ADF-8903-0E1D8A8DC72CQ46913074-5012F881-7511-4070-A844-4BF8F347DBAD
P50
description
Polish endocrinologist
@en
inchríneolaí Polannach
@ga
polski lekarz
@pl
name
Wojciech Zgliczyński
@ast
Wojciech Zgliczyński
@ca
Wojciech Zgliczyński
@cs
Wojciech Zgliczyński
@en
Wojciech Zgliczyński
@es
Wojciech Zgliczyński
@ga
Wojciech Zgliczyński
@gl
Wojciech Zgliczyński
@hr
Wojciech Zgliczyński
@hsb
Wojciech Zgliczyński
@it
type
label
Wojciech Zgliczyński
@ast
Wojciech Zgliczyński
@ca
Wojciech Zgliczyński
@cs
Wojciech Zgliczyński
@en
Wojciech Zgliczyński
@es
Wojciech Zgliczyński
@ga
Wojciech Zgliczyński
@gl
Wojciech Zgliczyński
@hr
Wojciech Zgliczyński
@hsb
Wojciech Zgliczyński
@it
altLabel
Wojciech Stanisław Zgliczyński
@pl
Wojciech Zgliczynski
@en
prefLabel
Wojciech Zgliczyński
@ast
Wojciech Zgliczyński
@ca
Wojciech Zgliczyński
@cs
Wojciech Zgliczyński
@en
Wojciech Zgliczyński
@es
Wojciech Zgliczyński
@ga
Wojciech Zgliczyński
@gl
Wojciech Zgliczyński
@hr
Wojciech Zgliczyński
@hsb
Wojciech Zgliczyński
@it
P214
P106
P1153
6603902912
P1412
P1559
Wojciech Zgliczyński
@pl
P19
P21
P213
0000 0001 1264 8259
P214
P27
P31
P3124
P496
0000-0002-7283-4755
P569
1957-01-19T00:00:00Z
P734
P7859
viaf-164224708